Bristol-Myers Squibb Co (NYSE:BMY) plunged -0.67% during previous trade, a total of 7M shares exchanged hands compared with its average trading volume of 10.14M shares whereas its relative volume is 0.52. The institutional investor owned 325,956 shares of the biopharmaceutical company's stock after buying an additional 97,990 shares during the period.
Other large investors also recently added to or reduced their stakes in the company. The Return on Investment (ROI) ratio of Bristol-Myers Squibb Company (BMY) is 20 percent. Charter Trust Co. now owns 48,026 shares of the biopharmaceutical company's stock valued at $2,590,000 after buying an additional 357 shares in the last quarter. Penserra Capital Management LLC raised its stake in shares of Bristol-Myers Squibb by 95.3% in the third quarter. First New York Securities LLC NY bought a new stake in Bristol-Myers Squibb during the third quarter worth about $108,000. Venator Capital Management Ltd. owns 560,880 shares or 5.32% of their United States portfolio. Ltd. raised its stake in Bristol-Myers Squibb by 428.0% in the fourth quarter.
Alcoa Corp's consensus price target is around $42.91 a share. Spirit of America Management Corp NY now owns 14,000 shares of the biopharmaceutical company's stock valued at $755,000 after buying an additional 5,300 shares in the last quarter.
Moving average is significant analytical tool used to discover current price trends and the possibility for a change in an established trend. Stock's intraday price range hit the peak level of $53.44 and touched the lowest level of $52.94. The original version of this news story can be read at https://www.chaffeybreeze.com/2017/04/13/pekin-singer-strauss-asset-management-il-buys-1200-shares-of-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, January 26th. The biopharmaceutical company reported $0.63 EPS for the quarter, missing the consensus estimate of $0.67 by $0.04. The business earned $5.24 billion during the quarter, compared to analyst estimates of $5.14 billion.
Bristol-Myers Squibb Company (BMY) is now showing its ROA (Return on Assets) of 13.5%. Equities research analysts expect that Bristol-Myers Squibb Co will post $2.80 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, May 1st. Investors of record on Friday, April 7th will be given a dividend of $0.39 per share. The ex-dividend date is Wednesday, April 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.94%. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 58.87%. Macnealy Hoover Inv Management has invested 0.79% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & global trademark & copyright law. Bristol-Myers Squibb Co has a 12-month low of $46.01 and a 12-month high of $77.12. The price to earnings growth is 1.46 and the price to sales ratio is 17. Leerink Swann also issued estimates for Bristol-Myers Squibb's Q3 2017 earnings at $0.67 EPS, Q4 2017 earnings at $0.67 EPS, FY2017 earnings at $2.74 EPS and FY2018 earnings at $2.67 EPS. Analysts have placed a $55.41 price target on Bristol-Myers Squibb Company, suggesting a 3.86% gain from recent close. Zacks Investment Research upgraded Bristol-Myers Squibb from a "sell" rating to a "hold" rating in a research note on Tuesday, January 24th. UBS maintained the shares of BMY in report on Friday, August 19 with "Buy" rating.
Among 16 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 7 Hold.
A trend analysis is a method of analysis that allows traders to predict what will happen with a stock in the future.
In other news, Director Theodore R. Samuels II purchased 12,000 shares of the firm's stock in a transaction dated Monday, February 27th. The number of shares now owned by investors are 1.67 bln. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The average volume stands around 13.27 million shares. Following the completion of the acquisition, the director now owns 12,000 shares in the company, valued at approximately $681,240. The disclosure for this purchase can be found here. Last year, it had about $4.39 billion of revenue. The stock declined 0.34% or $0.18 reaching $53.24 on the news.
In the announcement, Dr. Fouad Namouni, Bristol-Myers' head of oncology development and medical divisions, said the company would continue to battle the disease. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.